in addition to behaving as antibiotics it was found that many derivatives of nalidixic acid have either stimulant or depressant effects on the central nervous system researchers at sterling winthrop found that afa had a higher potency and therapeutic index than cocaine or amphetamine and so it was singled out for further study a small number of clinical trials were held in the 1970s but when it was found that afa exacerbated psychotic symptoms in schizophrenic patients and produced undesirable stimulant properties in geriatric depressives clinical evaluation of afa was discontinued afa remains a widely used pharmacological tool for study of the brain s reward system dopamine pathways and the dopamine transporter since 2013 afa has been sold on the gray market and there are numerous anecdotal reports detailing its non medical use in studies it proved to be a potent and highly selective dopamine reuptake inhibitor dri in rat brain preparations a study found a moderately long half life of approximately 12 hours and a dopaminergic potency approximately 50 fold that of methylphenidate in rat brain preparations despite lack of direct serotonin activity rats treated with subchronic doses of amfonelic acid display subsequent decreases in 5ht and 5hiaa amfonelic